新生血管性年龄相关性黄斑变性接受雷珠单抗或阿柏西普治疗后黄斑萎缩增长率的相关因素
本研究基于两项设计相同的前瞻性研究,纳入接受雷珠单抗或阿柏西普并按观察-计划可变剂量方案治疗的新生血管性年龄相关性黄斑变性(nAMD)患眼109只(来自101例患者,平均年龄80.6岁),在2年内出现黄斑萎缩(MA)的患眼中分析MA增长率的相关因素。平均平方根转换后MA增长率为0.54±0.34 mm/年;多因素分析证实基线视力较低(p=0.008)和色素上皮脱离厚度大于200 µm(p=0.035)与MA增长率显著相关,而药物种类或注射次数与MA增长率无关。
要点
- 平均平方根转换后MA增长率为0.54±0.34 mm/年,基于109只患眼。
- 多因素分析显示基线视力较低(p=0.008)与MA增长率显著相关。
- 色素上皮脱离厚度大于200 µm与MA增长率显著相关(p=0.035)。
核心结论
- MA增长率与基线视力较低和色素上皮脱离厚度大于200 µm相关,与所用药物或注射次数无关。
- 新生血管眼MA增长率与非新生血管对侧眼MA增长率显著相关(n=61;p=0.003)。
研究设计与样本
- 研究为两项设计相同的前瞻性研究,分别使用雷珠单抗或阿柏西普,均采用观察-计划可变剂量方案。
- 分析2年内出现MA的109只患眼(来自101例患者,平均年龄80.6岁)。
- 对MA面积作平方根转换后,计算基线至2年终点的MA增长率,并行单因素和多因素分析。
主要发现
- 平均平方根转换后MA增长率为0.54±0.34 mm/年。
- 单因素分析显示MA增长率与基线视力较低(p=0.001)、视网膜下组织复合体较厚(p=0.006)显著相关。
- 单因素分析中,色素上皮脱离的存在(p=0.057)和脉络膜新生血管亚型(p=0.069)与MA增长率接近显著相关。
- 多因素分析证实基线视力较低(p=0.008)和色素上皮脱离厚度大于200 µm(p=0.035)与MA增长率显著相关。
- 新生血管眼MA增长率与非新生血管对侧眼MA增长率显著相关(n=61;p=0.003)。
关键数值与推荐
- MA增长率以平方根转换后计算,平均为0.54±0.34 mm/年。
- 多因素分析中基线视力较低的p=0.008,色素上皮脱离厚度大于200 µm的p=0.035。
- 单因素分析中基线视力较低p=0.001,视网膜下组织复合体较厚p=0.006。
- 单因素分析中色素上皮脱离存在p=0.057,脉络膜新生血管亚型p=0.069。
- 新生血管眼与非新生血管对侧眼MA增长率相关分析的n=61,p=0.003。
临床怎么用
- 在采用观察-计划可变剂量方案时,应关注基线视力较低和色素上皮脱离厚度大于200 µm的患眼,其MA增长可能更快。
- 药物选择或注射次数并非MA增长率的显著相关因素,随访中应重视眼部结构因素。
- 对侧眼存在MA时,可提示新生血管眼MA增长风险,需加强双眼随访监测。
局限性
- 原文摘要未报告研究局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND/AIMS: To investigate the factors associated with macular atrophy (MA) growth rates in neovascular age-related macular degeneration treated with either ranibizumab or aflibercept. METHODS: We obtained data from two identical prospective studies using ranibizumab or aflibercept under observe-and-plan variable dosing regimens. We analysed eyes that presented MA within 2 years. After applying square root transformations to MA sizes, we calculated MA growth rate from baseline to the year 2 endpoint and used univariate and multivariate analyses to detect ocular and treatment factors associated with the MA growth rate. RESULTS: Included were 109 eyes from 101 patients (mean age 80.6 years). The mean square-root-transformed MA growth rate was 0.54±0.34 mm/year. The univariate analyses revealed that MA growth rates were significantly associated with lower baseline visual acuities (p=0.001) and thicker subretinal tissue complexes (p=0.006) and near-significantly associated with the presence of pigment epithelium detachment (p=0.057) and choroidal neovascularisation subtypes (p=0.069). Our multivariate analysis confirmed the significance of lower baseline visual acuities (p=0.008) and pigment epithelium detachments higher than 200 µm (p=0.035). Furthermore, MA growth rates in neovascular eyes significantly correlated with MA growth rates in non-neovascular fellow eyes (n=61; p=0.003). CONCLUSION: MA growth rates were associated with ocular factors in the study eyes and the fellow eyes but not with the drug or the number of injections within this variable dosing regimen.
引用
- Mantel I, Zola M, De Massougnes S, et al. Factors influencing macular atrophy growth rates in neovascular age-related macular degeneration treated with ranibizumab or aflibercept according to an observe-and-plan regimen. Br J Ophthalmol. 2018. PMID: 30166328. doi:10.1136/bjophthalmol-2018-312430
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。